Back on December 4 I looked at the charts of Halozyme Therapeutics (HALO) , a biotechnology firm focused on novel biological and drug delivery approaches. The chart was pointed up and the indicators were bullish and I wrote that, "I have no understanding or knowledge of the company's fundamentals so you will have to do your own research. What I do know is the stock has made a good base pattern that can support further price gains, in my opinion. Trade it from the long side with a $35 sell stop."
More from Investing
For many investors, the best way to sell is to have a highly mechanical system that removes subjectivity.
Here are the three highest yielding Dividend Aristocrats available right now.
This action is primarily caused by poor positioning, rather than a sudden improvement in fundamentals.